Literature DB >> 28353282

LRRK2 and the Immune System.

Nicolas L Dzamko1,2.   

Abstract

Polymorphisms in leucine-rich repeat kinase 2 (LRRK2) have been linked to familial Parkinson's disease, increased risk of sporadic Parkinson's disease, increased risk of Crohn's inflammatory bowel disease, and increased susceptibility to leprosy. As well as LRRK2 mutations, these diseases share in common immune dysfunction and inflammation. LRRK2 is highly expressed in particular immune cells and has been biochemically linked to the intertwined pathways regulating inflammation, mitochondrial function, and autophagy/lysosomal function. This review outlines what is currently understood about LRRK2 function in the immune system and the potential implications of LRRK2 dysfunction for diseases genetically linked to this enigmatic enzyme.

Entities:  

Keywords:  Crohn’s disease; Cytokine; Inflammation; Innate immunity; Kinase; Parkinson’s disease

Mesh：

Substances：

Year:  2017        PMID： 28353282     DOI： 10.1007/978-3-319-49969-7_7

Source DB:  PubMed          Journal:  Adv Neurobiol


  15 in total

1.  Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.

Authors:  Isabella Russo; Alice Kaganovich; Jinhui Ding; Natalie Landeck; Adamantios Mamais; Tatiana Varanita; Alice Biosa; Isabella Tessari; Luigi Bubacco; Elisa Greggio; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2019-05-15       Impact factor: 5.996

2.  LRRK2 mutation alters behavioral, synaptic, and nonsynaptic adaptations to acute social stress.

Authors:  Christopher A Guevara; Bridget A Matikainen-Ankney; Nebojsa Kezunovic; Katherine LeClair; Alexander P Conway; Caroline Menard; Meghan E Flanigan; Madeline Pfau; Scott J Russo; Deanna L Benson; George W Huntley
Journal:  J Neurophysiol       Date:  2020-05-06       Impact factor: 2.714

3.  Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

Authors:  Marta San Luciano; Caroline M Tanner; Cheryl Meng; Connie Marras; Samuel M Goldman; Anthony E Lang; Eduardo Tolosa; Birgitt Schüle; J William Langston; Alexis Brice; Jean-Christophe Corvol; Stefano Goldwurm; Christine Klein; Simone Brockman; Daniela Berg; Kathrin Brockmann; Joachim J Ferreira; Meriem Tazir; George D Mellick; Carolyn M Sue; Kazuko Hasegawa; Eng King Tan; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2020-07-14       Impact factor: 10.338

4.  Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.

Authors:  Ruwani S Wijeyekoon; Deborah Kronenberg-Versteeg; Kirsten M Scott; Shaista Hayat; Wei-Li Kuan; Jonathan R Evans; David P Breen; Gemma Cummins; Joanne L Jones; Menna R Clatworthy; R Andres Floto; Roger A Barker; Caroline H Williams-Gray
Journal:  Brain Behav Immun       Date:  2020-01-30       Impact factor: 19.227

Review 5.  Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention.

Authors:  Sara A Ferreira; Marina Romero-Ramos
Journal:  Front Cell Neurosci       Date:  2018-08-06       Impact factor: 5.505

6.  LRRK2 in Infection: Friend or Foe?

Authors:  Susanne Herbst; Maximiliano G Gutierrez
Journal:  ACS Infect Dis       Date:  2019-04-05       Impact factor: 5.084

7.  Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72.

Authors:  Carl Laflamme; Paul M McKeever; Rahul Kumar; Julie Schwartz; Mahshad Kolahdouzan; Carol X Chen; Zhipeng You; Faiza Benaliouad; Opher Gileadi; Heidi M McBride; Thomas M Durcan; Aled M Edwards; Luke M Healy; Janice Robertson; Peter S McPherson
Journal:  Elife       Date:  2019-10-15       Impact factor: 8.140

8.  A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts.

Authors:  Tianxia Li; Bo Ning; Lingbo Kong; Bingling Dai; Xiaofei He; Joseph M Thomas; Akira Sawa; Christopher A Ross; Wanli W Smith
Journal:  Cells       Date:  2021-02-23       Impact factor: 6.600

9.  The C-Terminal Domain of LRRK2 with the G2019S Substitution Increases Mutant A53T α-Synuclein Toxicity in Dopaminergic Neurons In Vivo.

Authors:  Noémie Cresto; Camille Gardier; Marie-Claude Gaillard; Francesco Gubinelli; Pauline Roost; Daniela Molina; Charlène Josephine; Noëlle Dufour; Gwenaëlle Auregan; Martine Guillermier; Suéva Bernier; Caroline Jan; Pauline Gipchtein; Philippe Hantraye; Marie-Christine Chartier-Harlin; Gilles Bonvento; Nadja Van Camp; Jean-Marc Taymans; Karine Cambon; Géraldine Liot; Alexis-Pierre Bemelmans; Emmanuel Brouillet
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

10.  The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease.

Authors:  Shalini Padmanabhan; Brian K Fiske; Marco A S Baptista
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.